After a multiyear incubation period at New York-based Pfizer Inc., Springworks Therapeutics LLC sprang to life with four Pfizer-derived candidates and an oversubscribed $103 million kitty to see them to the next stage of development. The syndicate for the company’s series A included Bain Capital Life Sciences, Bain Capital Double Impact, Orbimed and Lifearc (formerly MRC Technology), along with Pfizer, which also handed over global rights to the initial compounds.